Navigation Links
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
Date:9/17/2007

of the mechanisms of resistance in malignant gliomas is AGT. We are hoping that we can deplete the level of AGT with Temodar(R) and that the combination of agents will improve anti-tumor responses and outcomes. To date there is no standard therapy for malignant gliomas that recur; if we can increase progression- free and overall survival with this combination, we will be able to help patients."

Ann Cahill, Vice President, Clinical Development, said, "Despite decades of research, there has been little progress in the treatment of malignant gliomas which recur after primary therapy. We are pleased to support Dr. Raizer's study of Cloretazine(R) (VNP40101M) in this patient population."

Cloretazine(R) (VNP40101M) has previously been evaluated as a single agent in a Phase II clinical trial in patients with recurrent glioblastoma multiforme (Badruddoja MA et al, 2007 Neuro-Oncology; 9: 70-74). In addition, a Phase I trial of Cloretazine(R) (VNP40101M) as a single agent in pediatric brain tumors was recently completed. Data from this trial were presented at the American Society of Clinical Oncology Annual Meeting in June 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) in small cell lung cancer and adult brain tumors are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company is seek
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... June 30, 2014 on Thursday, July 31, 2014, after the ... and chief executive officer, will host a conference call to ... p.m. Pacific Time (PT). The press release ... be accessed through a link that is posted on the ...
(Date:7/22/2014)... , July 22, 2014  Edwards Lifesciences Corporation ... the science of heart valves and hemodynamic monitoring, announced ... today served as an expert panelist at the ... Subcommittee on Health to discuss medical device innovation at ... to Ongoing Evidence Development and Communication." "Edwards ...
(Date:7/22/2014)... July 22, 2014  Jazz Pharmaceuticals plc (Nasdaq: ... its 2014 second quarter financial results on Tuesday, August ... Company management will host a live audio webcast immediately ... to provide a business and financial update and discuss ... may access the live audio webcast via the Investors ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 3Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2
(Date:7/23/2014)... On July 21, 2014, My Positive Perspective host ... for an episode that spoke about the group Darkness to ... to talk some about the formation of the group, Tracey ... was started right here in Charleston, originally it was called ... survivors of sexual abuse. Their purpose has shifted to educating ...
(Date:7/23/2014)... As the push for marriage ... understanding the unique circumstances and special needs of ... To help lesbians pursue parenthood with knowledge and ... hosting a free, educational event about pregnancy and ... lesbian couples, not knowing legal and medical options ...
(Date:7/23/2014)... ANTONIO (July 22, 2014) Mouse models of human ... dramatic tumor shrinkage without damage to surrounding tissues, researchers ... at The University of Texas Health Science Center at ... intellectual property on results of the study, which is ... Late diagnosis, low survival , Oral squamous ...
(Date:7/23/2014)... Follow us on LinkedIn ... proportions in both developed and developing countries alike. Rising ... growing preference for processed food, and sedentary lifestyles present ... regarded a disease by itself, obesity is known to ... diabetes, hypertension, cardiovascular risks as well as cancer. The ...
(Date:7/23/2014)... 23, 2014 The Case Management Society of ... Day on the Hill, a one-day event that will bring ... awareness to Congress on the importance of case management to ... on September 10, 2014, at the U.S. Capitol Visitors Center ... Hill provides participants with the opportunity to play a direct ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Airs Episode to Raise Attention to the Group Darkness to Light 2Health News:Gay Women’s Gathering ™ in Chicago: An Evening about Lesbian Pregnancy 2Health News:Gay Women’s Gathering ™ in Chicago: An Evening about Lesbian Pregnancy 3Health News:Gay Women’s Gathering ™ in Chicago: An Evening about Lesbian Pregnancy 4Health News:Anti-pain agent shrinks oral cancers, leaves healthy tissues alone 2Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 2Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 3Health News:Surging Obesity Rates Drives Demand for Bariatric (Obesity) Surgical Devices, According to New Report by Global Industry Analysts, Inc. 4Health News:CMSA Launches Registration for the 2014 Day on the Hill 2
... on high alert Wednesday following the first confirmed outbreak of ... thousands of poultry were slaughtered in the Mekong// Delta. ... southern Ca Mau and Bac Lieu provinces, after tests on ... H5N1 strain of avian influenza., ,'We have begun to ...
... conducted by a US research company has highlighted the ... formidable health// problem facing society and their children today. ... 800 adults, found that nearly 27% named 'obesity', as ... insurance followed next with 16% strongly advocating action, ...
... North Carolina at Chapel Hill suggested that low LDL ... ,LDL stands for low density lipoprotein; the low ... Previously associations have been made between LDL and cardiovascular ... Parkinson's disease have a lower occurrence of heart attack ...
... the University of Texas M. D. Anderson Cancer Center suggest ... span of 40 years reduced the tumor growth in the// ... ,The Journal of the National Cancer Institute issued ... drug cromolyn is three times more effective than just the ...
... holding her husband’s hand, says a study. This is indeed ... of marriage// is losing ground. ,A new study ... Virginia, finds that women in a threatening situation show signs ... has been observed in brain scans. ,The researchers, ...
... Andy Kerr will receive Christmas cards from active members ... poor quality of treatment// offered to Chronic Obstructive Pulmonary ... charity suggests that clinical standards be set, to ensure ... ,COPD or Chronic Obstructive Pulmonary Disease is a term ...
Cached Medicine News:Health News:Low LDL Levels Lead to Parkinson's Disease 2Health News:Anti Allergy Drugs Reduce Tumor Growth 2Health News:Anti Allergy Drugs Reduce Tumor Growth 3
Plus cylinders only trial lens set....
This is a reduced form of the 100 Hue test and is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score. Kit includes 100 score pads....
... The L'Anthony 15 disc test (P/N ... for copying, and comprehensive instructions. P/N LD15C ... supply of finger tip covers for the ... and accuracy of the color discs). Beware ...
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Medicine Products: